0001203311-23-000075.txt : 20230817
0001203311-23-000075.hdr.sgml : 20230817
20230817204708
ACCESSION NUMBER: 0001203311-23-000075
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230815
FILED AS OF DATE: 20230817
DATE AS OF CHANGE: 20230817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SIMPSON TODD E
CENTRAL INDEX KEY: 0001216477
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-32405
FILM NUMBER: 231183594
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seagen Inc.
CENTRAL INDEX KEY: 0001060736
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 911874389
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4255274000
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: SEATTLE GENETICS INC /WA
DATE OF NAME CHANGE: 20001116
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2023-08-15
0
0001060736
Seagen Inc.
SGEN
0001216477
SIMPSON TODD E
21823 30TH DRIVE SE
BOTHELL
WA
98021
0
1
0
0
Chief Financial Officer
1
Common Stock
2023-08-15
4
A
0
14746
0.0
A
133692
D
Common Stock
2023-08-16
4
D
0
1106
193.8689
D
132586
D
Common Stock
2023-08-16
4
D
0
861
193.8689
D
131725
D
Common Stock
2023-08-16
4
D
0
1540
193.8689
D
130185
D
These shares represent restricted stock units and will be settled in common stock upon vesting. 40% of the reporting person's annual equity award was granted in the form of performance stock units, which are not reflected here, and will be treated the same as these restricted stock units in the event the transaction with Pfizer
closes.
Shares shall vest at a rate of 25% on each anniversary of August 15, 2023 until all shares are fully vested at the end of four years.
Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/3/2021 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/5/2020 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 10/15/2022 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
By: /s/ Jessica Nielsen Causey For: Todd E Simpson
2023-08-17